The effect of Thymoquinone on Peripheral Blood Mononuclear Cells (PBMCs) viability of patients with B-Chronic Lymphocytic Leukemia

References

• 1.
  Ten Hacken E, Burger JA. Microenvironment interactions and B-cell receptor signaling in chronic lymphocytic leukemia: Implications for disease pathogenesis and treatment. Biochim Biophys Acta 2016; 1863: 401-413.
• 2.
  Kokhaei P. B-cell chronic lymphocyte leukemia (B-CLL). Koomesh 1386; 9: 1-12. (Persian).
• 3.
  Koohi F, Salehiniya H, Shamlou R, Eslami S, Ghojogh ZM, Kor Y, Rafiemanesh H. Leukemia in Iran: Epidemiology and morphology trends. Asian Pacific J Cancer Prev 2015; 16: 7759-7763.
• 4.
  Pulte D, Redaniel MT, Bird J, Jeffreys M. Survival for patients with chronic leukemias in the US and Britain: agerelated disparities and changes in the early 21st century. Eur J Haematol 2015; 94: 540-545.
• 5.
  Visone R, Veronese A, Rassenti LZ, Balatti V, Pearl DK, Acunzo M, et al. miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood 2011; 118: 3072-3079.
• 6.
  Sadeghnejad A, Hemati M, Pashaei M, Rasouli Nejad Z, Ghahremanfard F, Kokhaei P. Effect of IL-27 on activity of bone marrow NK cells of patient with B-chronic lymphocytic leukemia in vitro. Koomesh 1399; 23: 131-138. (Persian)##https://doi.org/10.29252/koomesh.23.1.131.
• 7.
  Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N E J Med 2014; 370: 1101-1110.
• 8.
  Hallek M, Fischer K, Fingerle-Rowson G, Fink A, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. The Lancet 2010; 376: 1164-1174.
• 9.
  Taylor WF, Jabbarzadeh E. The use of natural products to target cancer stem cells. Am J Cancer Res 2017; 7: 1588-1605.
• 10.
  Parikh SA. Chronic lymphocytic leukemia treatment algorithm 2018. Blood Cancer J 2018; 8: 93.
• 11.
  Sauter ER. Cancer prevention and treatment using combination therapy with natural compounds. Exp Rev Clin Pharmacol 2020; 13: 265-285.
• 12.
  Ratovitski EA. Anticancer natural compounds as epigenetic modulators of gene expression. Curr Genom 2017; 18: 175-205.
• 13.
  Fatfat Z, Fatfat M, Gali-Muhtasib H. Therapeutic potential of thymoquinone in combination therapy against cancer and cancer stem cells. World J Clin Oncol 2021; 12: 522-543.
• 14.
  Ahmad A, Mishra RK, Vyawahare A, Kumar A, Rehman MU, Qamar W, et al. Thymoquinone (2-Isopropyl-5-methyl-1, 4-benzoquinone) as a chemopreventive/anticancer agent: Chemistry and biological effects. Saudi Pharmace J 2019; 27: 1113-1126.
• 15.
  Amizadeh S, Rashtchizadeh N, Khabbazi A, Ghorbanihaghjo A, Ebrahimi AA, Vatankhah AM, et al. Effect of Nigella sativa oil extracts on inflammatory and oxidative stress markers in Behcet's disease: A randomized, double-blind, placebo-controlled clinical trial. Avicenna J Phytomed 2020; 10: 181.
• 16.
  Nawarathne NW, Wijesekera K, Wijayaratne WM, Napagoda M. Development of novel topical cosmeceutical formulations from Nigella sativa L. with antimicrobial activity against acne-causing microorganisms. Scientific World J 2019; 2019.
• 17.
  Hamada F, Abdel-Aziz H, Badr F, Moustafa A, Rashad A. The mutagenic effect of praziquantel in S. mansoni-infected mice. Arab J Lab 1992; 18: 301-311.
• 18.
  Salim EI, Fukushima S. Chemopreventive potential of volatile oil from black cumin (Nigella sativa L.) seeds against rat colon carcinogenesis. Nutr Cancer 2003; 45: 195-202.
• 19.
  Woo CC, Loo SY, Gee V, Yap CW, Sethi G, Kumar AP, Tan KH. Anticancer activity of thymoquinone in breast cancer cells: possible involvement of PPAR- pathway. Biochem Pharmacol 2011; 82: 464-475.
• 20.
  Awad E. In vitro decreases of the fibrinolytic potential of cultured human fibrosarcoma cell line, HT1080, by Nigella sativa oil. Phytomedicine 2005; 12: 100-107.
• 21.
  Bargi R, Hosseini M, Asgharzadeh F, Khazaei M, Shafei MN, Beheshti F. Protection against blood-brain barrier permeability as a possible mechanism for protective effects of thymoquinone against sickness behaviors induced by lipopolysaccharide in rats. Jundishapur J Nat Pharmac Prod 2021; 16. (Persian)##https://doi.org/10.5812/jjnpp.67765.
• 22.
  Khan MA, Tania M, Wei C, Mei Z, Fu S, Cheng J, et al. Thymoquinone inhibits cancer metastasis by downregulating TWIST1 expression to reduce epithelial to mesenchymal transition. Oncotarget 2015; 6: 19580.
• 23.
  Khan MA, Tania M, Fu S, Fu J. Thymoquinone, as an anticancer molecule: from basic research to clinical investigation. Oncotarget 2017; 8: 51907.
• 24.
  Peng L, Liu A, Shen Y, Xu HZ, Yang SZ, Ying XZ, et al. Antitumor and anti-angiogenesis effects of thymoquinone on osteosarcoma through the NF-B pathway. Oncol Rep 2013; 29: 571-578.
• 25.
  Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dhner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
• 26.
  Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood 2015; 125: 2062-2067.
• 27.
  Edris AE. Anti-cancer properties of Nigella spp. essential oils and their major constituents, thymoquinone and beta-elemene. Curr Clin Pharmacol 2009; 4: 43-46.
• 28.
  Cragg GM, Grothaus PG, Newman DJ. Impact of natural products on developing new anti-cancer agents. Chem Rev 2009; 109: 3012-3043.
• 29.
  Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood 2015; 125: 2062-2067.
• 30.
  Yi T, Cho SG, Yi Z, Pang X, Rodriguez M, Wang Y, et al. Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Mol Cancer Ther 2008; 7: 1789-96.
• 31.
  Al-Johar D, Shinwari N, Arif J, Al-Sanea N, Jabbar AA, El-Sayed R, et al. Role of Nigella sativa and a number of its antioxidant constituents towards azoxymethane-induced genotoxic effects and colon cancer in rats. Phytother Res 2008; 22: 1311-1323.
• 32.
  Salim LZ, Othman R, Abdulla MA, Al-Jashamy K, Ali HM, Hassandarvish Pet al. Thymoquinone inhibits murine leukemia WEHI-3 cells in vivo and in vitro. PloS One 2014; 9: e115340.
• 33.
  Goldsworthy TL, Conolly RB, Fransson-Steen R. Apoptosis and cancer risk assessment. Mutat Res 1996; 365: 71-90.
• 34.
  Nagata S. Apoptotic DNA fragmentation. Exp Cell Res 2000; 256: 12-18.
• 35.
  Musalli MG, Hassan MA, Sheikh RA, Kalantan AA, Halwani MA, Zeyadi M, et al. Thymoquinone induces cell proliferation inhibition and apoptosis in acute myeloid leukemia cells: Role of apoptosis-related WT1 and BCL2 genes. Eur J Cell Sci 2019; 1: 2-9.##https://doi.org/10.34154/2019-EJCS-0101-02-09/euraass.
• 36.
  Samarghandian S, Azimi-Nezhad M, Farkhondeh T. Thymoquinone-induced antitumor and apoptosis in human lung adenocarcinoma cells. J Cell Physiol 2019; 234: 10421-10431.